Literature DB >> 9148917

Thyroid hormone-mediated enhancement of heterodimer formation between thyroid hormone receptor beta and retinoid X receptor.

T N Collingwood1, A Butler, Y Tone, R J Clifton-Bligh, M G Parker, V K Chatterjee.   

Abstract

A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands. In a mammalian two-hybrid assay, we have found that recruitment of a VP16-RXR chimera by a Gal4-TRbeta ligand-binding domain fusion is enhanced up to 50-fold by thyroid hormone (T3). This was also observed with a mutant fusion, Gal4-TR(L454A), lacking ligand-inducible activation function (AF-2) and unable to interact with putative coactivators, suggesting that the AF-2 activity of TR or intermediary cofactors is not involved in this effect. The wild-type and mutant Gal4-TR fusions also exhibited hormone-dependent recruitment of RXR in yeast. Hormone-dependent recruitment of RXR was also evident with another Gal4-TR mutant, AHTm, which does not interact with the nuclear receptor corepressor N-CoR, suggesting that ligand-enhanced dimerization is not a result of T3-induced corepressor release. Finally, we have shown that the interaction between RXR and TR is augmented by T3 in vitro, arguing against altered expression of either partner in vivo mediating this effect. We propose that ligand-dependent heterodimerization of TR and RXR in solution may provide a further level of control in nuclear receptor signaling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148917     DOI: 10.1074/jbc.272.20.13060

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  The activity of the activation function 2 of the human hepatocyte nuclear factor 4 (HNF-4alpha) is differently modulated by F domains from various origins.

Authors:  L Suaud; P Formstecher; B Laine
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Molecular basis for dimer formation of TRbeta variant D355R.

Authors:  Natalia Jouravel; Elena Sablin; Marie Togashi; John D Baxter; Paul Webb; Robert J Fletterick
Journal:  Proteins       Date:  2009-04

3.  A novel role for helix 12 of retinoid X receptor in regulating repression.

Authors:  J Zhang; X Hu; M A Lazar
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  Mechanistic principles in NR box-dependent interaction between nuclear hormone receptors and the coactivator TIF2.

Authors:  J Leers; E Treuter; J A Gustafsson
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

5.  Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression.

Authors:  J Zhang; I Zamir; M A Lazar
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

Review 6.  Mammalian synthetic biology: emerging medical applications.

Authors:  Zoltán Kis; Hugo Sant'Ana Pereira; Takayuki Homma; Ryan M Pedrigi; Rob Krams
Journal:  J R Soc Interface       Date:  2015-05-06       Impact factor: 4.118

7.  The rat thyroid hormone receptor (TR) Deltabeta3 displays cell-, TR isoform-, and thyroid hormone response element-specific actions.

Authors:  Clare B Harvey; J H Duncan Bassett; Padma Maruvada; Paul M Yen; Graham R Williams
Journal:  Endocrinology       Date:  2007-01-11       Impact factor: 4.736

8.  PLZF is a negative regulator of retinoic acid receptor transcriptional activity.

Authors:  Perrine J Martin; Marie-Hélène Delmotte; Pierre Formstecher; Philippe Lefebvre
Journal:  Nucl Recept       Date:  2003-09-06

9.  Moderate-intensity exercise alters markers of alternative activation in circulating monocytes in females: a putative role for PPARγ.

Authors:  J S Ruffino; N A Davies; K Morris; M Ludgate; L Zhang; R Webb; A W Thomas
Journal:  Eur J Appl Physiol       Date:  2016-06-23       Impact factor: 3.078

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.